Skip to main content
Journal ArticleOPEN ACCESS

Second-generation tricyclic pyrimido-pyrrolo-oxazine mTOR inhibitor with predicted blood-brain barrier permeability

RSC Medicinal Chemistry (2021) 12(4) 579-583
DOI: 10.1039/d0md00408a
7Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

Highly selective mTOR inhibitors have been discovered through the exploration of the heteroaromatic ring engaging the binding affinity region in mTOR kinase. Compound11showed predicted BBB permeability in a MDCK-MDR1 permeabilityin vitroassay, being the first pyrimido-pyrrolo-oxazine with potential application in the treatment of neurological disorders.

Cite

CITATION STYLE

APA

Borsari, C., Keles, E., Treyer, A., De Pascale, M., Hebeisen, P., Hamburger, M., & Wymann, M. P. (2021). Second-generation tricyclic pyrimido-pyrrolo-oxazine mTOR inhibitor with predicted blood-brain barrier permeability. RSC Medicinal Chemistry, 12(4), 579–583. https://doi.org/10.1039/d0md00408a

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free